The differences of biomarkers between colorectal cancer and its metastases have been compared [73,74], including KRAS/BRAF mutation and MSI status, indicating the importance of testing mutations in peritoneal metastasis and treating methods. The gene discussed is KRAS; the disease is colorectal cancer.